Laquinimod protects the optic nerve and retina in an experimental autoimmune encephalomyelitis model

Abstract Background The oral immunomodulatory agent laquinimod is currently evaluated for multiple sclerosis (MS) treatment. Phase II and III studies demonstrated a reduction of degenerative processes. In addition to anti-inflammatory effects, laquinimod might have neuroprotective properties, but it...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Anna T. Wilmes, Sabrina Reinehr, Sandra Kühn, Xiomara Pedreiturria, Laura Petrikowski, Simon Faissner, Ilya Ayzenberg, Gesa Stute, Ralf Gold, H. Burkhard Dick, Ingo Kleiter, Stephanie C. Joachim
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	BMC 2018-06-01
Edice:	Journal of Neuroinflammation
Témata:	Multiple sclerosis Laquinimod EAE Optic nerve Inflammation Demyelination
On-line přístup:	http://link.springer.com/article/10.1186/s12974-018-1208-3
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!